{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:40:43Z","timestamp":1790793643785,"version":"4.1.0"},"reference-count":210,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011898","name":"Marianne and Marcus Wallenberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003173","name":"Crafoordska Stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003173","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005753","name":"Kungliga Fysiografiska S\u00e4llskapet i Lund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005753","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02357","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T04:31:15Z","timestamp":1570768275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":134,"title":["Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells"],"prefix":"10.3389","volume":"10","author":[{"given":"Mattias","family":"Carlsten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"J\u00e4r\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ijc.2910160204","article-title":"Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity","volume":"16","author":"Herberman","year":"1975","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ijc.2910160205","article-title":"Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells","volume":"16","author":"Herberman","year":"1975","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/eji.1830050209","article-title":"Natural killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur J Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/eji.1830050208","article-title":"Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur J Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.immuni.2015.09.013","article-title":"Natural killer cell memory","volume":"43","author":"O'Sullivan","year":"2015","journal-title":"Immunity"},{"key":"B6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.it.2013.07.005","article-title":"Location and cellular stages of natural killer cell development","volume":"34","author":"Yu","year":"2013","journal-title":"Trends Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/ni.3482","article-title":"NK cells and type 1 innate lymphoid cells: partners in host defense","volume":"17","author":"Spits","year":"2016","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.3389\/fimmu.2018.02324","article-title":"Molecular mechanisms directing migration and retention of natural killer cells in human tissues","volume":"9","author":"Castriconi","year":"2018","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"Karre","year":"1986","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol Today"},{"key":"B11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","article-title":"Human NK cell education by inhibitory receptors for MHC class I","volume":"25","author":"Anfossi","year":"2006","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood-2009-01-201632","article-title":"Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors","volume":"114","author":"Bryceson","year":"2009","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20051143","article-title":"Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells","volume":"202","author":"Bryceson","year":"2005","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.4049\/jimmunol.167.4.2068","article-title":"A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells","volume":"167","author":"Screpanti","year":"2001","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1084\/jem.188.12.2375","article-title":"Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells","volume":"188","author":"Zamai","year":"1998","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.4049\/jimmunol.1003879","article-title":"TRAIL\/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells","volume":"187","author":"Iyori","year":"2011","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3389\/fimmu.2016.00251","article-title":"Recognition and regulation of T cells by NK Cells","volume":"7","author":"Pallmer","year":"2016","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2011-10-385377","article-title":"Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency","volume":"119","author":"Shaw","year":"2012","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jaci.2013.07.020","article-title":"Natural killer cell deficiency","volume":"132","author":"Orange","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.celrep.2013.11.041","article-title":"Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein\u2013Barr virus infection","volume":"5","author":"Chijioke","year":"2013","journal-title":"Cell Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fimmu.2018.00183","article-title":"Molecular basis for the recognition of herpes simplex virus type 1 infection by human natural killer cells","volume":"9","author":"Dai","year":"2018","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","article-title":"Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function","volume":"119","author":"Foley","year":"2012","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.4049\/jimmunol.1201964","article-title":"Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen","volume":"189","author":"Foley","year":"2012","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ni1114","article-title":"Interplay of natural killer cells and their receptors with the adaptive immune response","volume":"5","author":"Raulet","year":"2004","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.4049\/jimmunol.1000652","article-title":"NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses","volume":"186","author":"Salagianni","year":"2011","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3389\/fimmu.2018.01897","article-title":"Human innate lymphoid cells: their functional and cellular interactions in decidua","volume":"9","author":"Vacca","year":"2018","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.smim.2017.08.002","article-title":"Natural killer cell-mediated immunosurveillance of human cancer","volume":"31","author":"Malmberg","year":"2017","journal-title":"Semin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(00)03231-1","article-title":"Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population","volume":"356","author":"Imai","year":"2000","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1182\/bloodadvances.2017015230","article-title":"Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy","volume":"2","author":"Mastaglio","year":"2018","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","article-title":"NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy","volume":"28","author":"Guerra","year":"2008","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1084\/jem.20081611","article-title":"Accelerated tumor growth in mice deficient in DNAM-1 receptor","volume":"205","author":"Iguchi-Manaka","year":"2008","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrd4506","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens","volume":"14","author":"Childs","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.4049\/jimmunol.0901226","article-title":"Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells","volume":"183","author":"Carlsten","year":"2009","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","article-title":"Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction","volume":"109","author":"Fauriat","year":"2007","journal-title":"Blood."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/leu.2010.149","article-title":"Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome","volume":"24","author":"Carlsten","year":"2010","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood."},{"key":"B44","first-page":"2859","article-title":"Antileukemia activity of a natural killer cell line against human leukemias","volume":"4","author":"Yan","year":"1998","journal-title":"Clin Cancer Res"},{"key":"B45","first-page":"165","article-title":"Lysis of fresh leukemic blasts by interferon-activated human natural killer cells","volume":"3","author":"Pattengale","year":"1983","journal-title":"Nat Immun Cell Growth Regul"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/0145-2126(87)90158-5","article-title":"Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors","volume":"11","author":"Lotzova","year":"1987","journal-title":"Leuk Res"},{"key":"B47","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood.V87.6.2476.bloodjournal8762476","article-title":"Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture","volume":"87","author":"Cervantes","year":"1996","journal-title":"Blood."},{"key":"B48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2141.2002.03277.x","article-title":"Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission","volume":"116","author":"Torelli","year":"2002","journal-title":"Br J Haematol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4049\/jimmunol.176.2.864","article-title":"The decreased susceptibility of Bcr\/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation","volume":"176","author":"Cebo","year":"2006","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"473175","DOI":"10.1155\/2015\/473175","article-title":"NKG2D signaling leads to NK cell mediated lysis of childhood AML","volume":"2015","author":"Schlegel","year":"2015","journal-title":"J Immunol Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1182\/blood-2004-09-3548","article-title":"Analysis of the receptor\u2013ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)","volume":"105","author":"Pende","year":"2005","journal-title":"Blood."},{"key":"B53","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.bbmt.2010.01.019","article-title":"Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade","volume":"16","author":"Godal","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/leu.2010.158","article-title":"AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3","volume":"24","author":"Wunderlich","year":"2010","journal-title":"Leukemia"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1625015","DOI":"10.1155\/2016\/1625015","article-title":"Modeling of chronic myeloid leukemia: an overview of in vivo murine and human xenograft models","volume":"2016","author":"Sontakke","year":"2016","journal-title":"Stem Cells Int"},{"key":"B56","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41467-018-08166-x","article-title":"A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies","volume":"10","author":"Song","year":"2019","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/sj.leu.2404147","article-title":"Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice","volume":"20","author":"Guimar\u00e3es","year":"2006","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e64384","DOI":"10.1371\/journal.pone.0064384","article-title":"Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD\/SCID\/IL2Rg(null) mice","volume":"8","author":"Cany","year":"2013","journal-title":"PLoS One"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e1017701","DOI":"10.1080\/2162402X.2015.1017701","article-title":"Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer","volume":"4","author":"Cany","year":"2015","journal-title":"Oncoimmunology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fonc.2012.00032","article-title":"Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models","volume":"2","author":"Rettinger","year":"2012","journal-title":"Front Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3109\/14653241003786155","article-title":"Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients","volume":"12","author":"Siegler","year":"2010","journal-title":"Cytotherapy"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1038\/sj.leu.2403985","article-title":"Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD\/SCID mice","volume":"19","author":"Siegler","year":"2005","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2004-12-4825","article-title":"Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes","volume":"105","author":"Hsu","year":"2005","journal-title":"Blood."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood."},{"key":"B65","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1200\/JCO.2016.70.7059","article-title":"KIR3DL1\/HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation","volume":"35","author":"Boudreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"125553","DOI":"10.1172\/jci.insight.125553","article-title":"Adaptive NK cell reconstitution is associated with better clinical outcomes","volume":"4","author":"Cichocki","year":"2019","journal-title":"JCI Insight"},{"key":"B68","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e0123416","DOI":"10.1371\/journal.pone.0123416","article-title":"Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: a phase I trial","volume":"10","author":"Kottaridis","year":"2015","journal-title":"PLoS ONE"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1158\/1078-0432.CCR-15-1604","article-title":"Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients","volume":"22","author":"Curti","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","article-title":"Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML","volume":"24","author":"Bj\u00f6rklund","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bbmt.2018.03.019","article-title":"A phase 1 trial of CNDO-109-activated natural killer cells in patients with high-risk acute myeloid leukemia","volume":"24","author":"Fehniger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B74","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00262-008-0601-7","article-title":"Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by natural killer cells","volume":"58","author":"Verheyden","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood."},{"key":"B76","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/bjc.1988.221","article-title":"Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission","volume":"58","author":"Pizzolo","year":"1988","journal-title":"Br J Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fimmu.2017.00064","article-title":"Kinetics of cytotoxic lymphocytes reconstitution after induction chemotherapy in elderly AML patients reveals progressive recovery of normal phenotypic and functional features in NK cells","volume":"8","author":"Rey","year":"2017","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/sj.leu.2404080","article-title":"Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes","volume":"20","author":"Kiladjian","year":"2006","journal-title":"Leukemia"},{"key":"B79","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood.V76.2.401.401","article-title":"Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia","volume":"76","author":"Verfaillie","year":"1990","journal-title":"Blood."},{"key":"B80","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood.V88.6.2279.bloodjournal8862279","article-title":"CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis","volume":"88","author":"Pierson","year":"1996","journal-title":"Blood."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"B83","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1158\/2326-6066.CIR-17-0462","article-title":"Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML","volume":"6","author":"Ureshino","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/sj.bmt.1700756","article-title":"The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia","volume":"19","author":"Lowdell","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"B85","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1046\/j.1365-2141.2002.03495.x","article-title":"Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells","volume":"117","author":"Lowdell","year":"2002","journal-title":"Br J Haematol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.4049\/jimmunol.1500262","article-title":"Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion","volume":"195","author":"Khaznadar","year":"2015","journal-title":"J Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/ijlh.12594","article-title":"The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia","volume":"39","author":"Alcasid","year":"2017","journal-title":"Int J Lab Hematol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"49548","DOI":"10.18632\/oncotarget.17747","article-title":"NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia","volume":"8","author":"Chretien","year":"2017","journal-title":"Oncotarget"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e1307491","DOI":"10.1080\/2162402X.2017.1307491","article-title":"NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML","volume":"6","author":"Chretien","year":"2017","journal-title":"Oncoimmunology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"42569","DOI":"10.18632\/oncotarget.5559","article-title":"NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance","volume":"6","author":"Martner","year":"2015","journal-title":"Oncotarget"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1038\/leu.2017.151","article-title":"Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia","volume":"31","author":"Bernson","year":"2017","journal-title":"Leukemia"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1182\/blood-2018-09-874990","article-title":"The HLA-B-21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia","volume":"133","author":"Hallner","year":"2019","journal-title":"Blood."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2019.1581935","article-title":"Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine","volume":"2019","author":"Tsirogianni","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B94","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1182\/blood-2010-04-281675","article-title":"Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education","volume":"116","author":"Bj\u00f6rkstr\u00f6m","year":"2010","journal-title":"Blood."},{"key":"B95","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1172\/JCI85413","article-title":"MicroRNA-29b mediates altered innate immune development in acute leukemia","volume":"126","author":"Mundy-Bosse","year":"2016","journal-title":"J Clin Invest"},{"key":"B97","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3389\/fimmu.2015.00564","article-title":"Increased NK cell maturation in patients with acute myeloid leukemia","volume":"6","author":"Chretien","year":"2015","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/cyto.b.21349","article-title":"Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes","volume":"90","author":"Aggarwal","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e1041701","DOI":"10.1080\/2162402X.2015.1041701","article-title":"Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia","volume":"5","author":"Martner","year":"2016","journal-title":"Oncoimmunology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3389\/fimmu.2017.00573","article-title":"Natural killer defective maturation is associated with adverse clinical outcome in patients with acute myeloid leukemia","volume":"8","author":"Chretien","year":"2017","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ajh.21906","article-title":"Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission","volume":"86","author":"Dauguet","year":"2011","journal-title":"Am J Hematol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.leukres.2018.01.010","article-title":"Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response\u2014the final results of the D-first study","volume":"66","author":"Najima","year":"2018","journal-title":"Leuk Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2018.09.009","article-title":"High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice","volume":"49","author":"Crinier","year":"2018","journal-title":"Immunity"},{"key":"B104","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cell.2018.11.045","article-title":"Gene regulatory programs conferring phenotypic identities to human NK cells","volume":"176","author":"Collins","year":"2019","journal-title":"Cell"},{"key":"B105","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"B106","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","article-title":"Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo","volume":"25","author":"Woll","year":"2014","journal-title":"Cancer Cell"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood."},{"key":"B108","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1046\/j.1365-2141.2000.02341.x","article-title":"Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia","volume":"111","author":"Cho","year":"2000","journal-title":"Br J Haematol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000039748","article-title":"Detection of the BCR-ABL fusion gene in natural killer cells in patients with chronic myelogenous leukemia","volume":"104","author":"Min","year":"2000","journal-title":"Acta Haematol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4049\/jimmunol.168.2.643","article-title":"The BCR\/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients","volume":"168","author":"Nakajima","year":"2002","journal-title":"J Immunol"},{"key":"B111","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"key":"B112","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1182\/blood-2002-04-1172","article-title":"BCR\/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs)","volume":"101","author":"Chiorean","year":"2003","journal-title":"Blood."},{"key":"B113","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1046\/j.1365-2141.1996.4991043.x","article-title":"Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR\/abl-positive targets","volume":"93","author":"Silla","year":"1996","journal-title":"Br J Haematol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1158\/0008-5472.CAN-04-2675","article-title":"BCR\/ABL promotes dendritic cell-mediated natural killer cell activation","volume":"65","author":"Terme","year":"2005","journal-title":"Cancer Res"},{"key":"B115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V80.1.217.217","article-title":"Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ hybridization","volume":"80","author":"Gerritsen","year":"1992","journal-title":"Blood."},{"key":"B116","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood.V92.8.2886","article-title":"Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes","volume":"92","author":"Saitoh","year":"1998","journal-title":"Blood."},{"key":"B117","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1046\/j.1365-2141.2000.02294.x","article-title":"Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting","volume":"110","author":"Miura","year":"2000","journal-title":"Br J Haematol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1182\/blood-2016-10-743302","article-title":"Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms","volume":"129","author":"Tesi","year":"2017","journal-title":"Blood."},{"key":"B119","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-07-517151","article-title":"The evolution of cellular deficiency in GATA2 mutation","volume":"123","author":"Dickinson","year":"2014","journal-title":"Blood."},{"key":"B120","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s41375-018-0047-7","article-title":"Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis","volume":"32","author":"Arends","year":"2018","journal-title":"Leukemia"},{"key":"B122","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1182\/blood.V99.10.3661","article-title":"Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia","volume":"99","author":"Costello","year":"2002","journal-title":"Blood."},{"key":"B123","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1182\/blood-2006-07-035519","article-title":"Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors","volume":"109","author":"Epling-Burnette","year":"2007","journal-title":"Blood."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00262-011-1050-2","article-title":"Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands","volume":"60","author":"Sanchez-Correa","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B125","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2014","journal-title":"Haematologica"},{"key":"B126","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1002\/eji.201444500","article-title":"Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse","volume":"44","author":"Khaznadar","year":"2014","journal-title":"Eur J Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.3892\/ol.2018.8062","article-title":"Abnormal populations and functions of natural killer cells in patients with myelodysplastic syndromes","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol Lett"},{"key":"B128","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"key":"B129","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/icb.2011.15","article-title":"Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients","volume":"90","author":"Sanchez-Correa","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood-2007-07-100057","article-title":"Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways","volume":"111","author":"Coudert","year":"2008","journal-title":"Blood."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1182\/blood-2003-01-0019","article-title":"Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia","volume":"102","author":"Salih","year":"2003","journal-title":"Blood."},{"key":"B132","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.4049\/jimmunol.176.8.5108","article-title":"BCR\/ABL oncogene directly controls MHC class I chain-related molecule: a expression in chronic myelogenous leukemia","volume":"176","author":"Boissel","year":"2006","journal-title":"J Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cellimm.2006.03.002","article-title":"Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression","volume":"239","author":"Song","year":"2006","journal-title":"Cell Immunol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"7249","DOI":"10.4049\/jimmunol.180.11.7249","article-title":"Human tumor-derived exosomes down-modulate NKG2D expression","volume":"180","author":"Clayton","year":"2008","journal-title":"J Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","article-title":"Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses","volume":"189","author":"Hilpert","year":"2012","journal-title":"J Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/blood-2004-07-2585","article-title":"Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias","volume":"105","author":"Nowbakht","year":"2005","journal-title":"Blood."},{"key":"B137","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"B138","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.4049\/jimmunol.172.12.7335","article-title":"Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients","volume":"172","author":"Lee","year":"2004","journal-title":"J Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood-2018-03-838474","article-title":"Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function","volume":"132","author":"Scoville","year":"2018","journal-title":"Blood."},{"key":"B140","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","article-title":"The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells","volume":"22","author":"Gon\u00e7alves Silva","year":"2017","journal-title":"EBioMedicine"},{"key":"B141","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4\u20131BB: mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood."},{"key":"B142","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1182\/blood-2009-06-227934","article-title":"CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells","volume":"115","author":"Baessler","year":"2010","journal-title":"Blood."},{"key":"B143","doi-asserted-by":"publisher","first-page":"e1196308","DOI":"10.1080\/2162402X.2016.1196308","article-title":"Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing","volume":"5","author":"Kearney","year":"2016","journal-title":"Oncoimmunology"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood-2013-09-526590","article-title":"Immune evasion by oncogenic proteins of acute myeloid leukemia","volume":"123","author":"Elias","year":"2014","journal-title":"Blood."},{"key":"B145","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/bmt.2008.380","article-title":"HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94\/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT","volume":"43","author":"Nguyen","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B146","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1046\/j.1365-2249.2001.01692.x","article-title":"Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function\u2014Implications for the adoptive immunotherapy of leukaemia","volume":"126","author":"Orleans-Lindsay","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"B147","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood.V96.5.1961","article-title":"Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine","volume":"96","author":"Mellqvist","year":"2000","journal-title":"Blood."},{"key":"B148","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1189\/jlb.0512257","article-title":"Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes","volume":"93","author":"Aurelius","year":"2013","journal-title":"J Leukoc Biol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1189\/jlb.5VMA1116-454R","article-title":"NOX2-dependent immunosuppression in chronic myelomonocytic leukemia","volume":"102","author":"Aurelius","year":"2017","journal-title":"J Leukoc Biol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.leukres.2014.12.001","article-title":"The bone marrow microenvironment is a critical player in the NK cell response against acute myeloid leukaemia in vitro","volume":"39","author":"Vasold","year":"2015","journal-title":"Leuk Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12307-012-0125-8","article-title":"Shaping of NK cell responses by the tumor microenvironment","volume":"6","author":"Stojanovic","year":"2013","journal-title":"Cancer Microenviron"},{"key":"B152","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1182\/blood-2012-03-415364","article-title":"Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells","volume":"119","author":"Gill","year":"2012","journal-title":"Blood."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1080\/14740338.2017.1382472","article-title":"High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions","volume":"16","author":"Marabondo","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"B154","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00672.x","article-title":"A phase II trial of interleukin-2 in myelodysplastic syndromes","volume":"101","author":"Nand","year":"1998","journal-title":"Br J Haematol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1200\/JCO.2008.17.0472","article-title":"Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: cancer and leukemia group B study 9720","volume":"26","author":"Sigal","year":"2008","journal-title":"J Clin Oncol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1365-3083.2009.02303.x","article-title":"Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol","volume":"70","author":"Romero","year":"2009"},{"key":"B157","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1182\/blood-2005-10-4073","article-title":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial","volume":"108","author":"Brune","year":"2006","journal-title":"Blood."},{"key":"B158","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.4049\/jimmunol.153.11.4940","article-title":"Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites","volume":"153","author":"Hellstrand","year":"1994","journal-title":"J Immunol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"46466","DOI":"10.18632\/oncotarget.10191","article-title":"Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation","volume":"7","author":"Cuapio","year":"2016","journal-title":"Oncotarget"},{"key":"B160","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/jir.2017.0101","article-title":"IL-2 and beyond in cancer immunotherapy","volume":"38","author":"Wrangle","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00262-017-2040-9","article-title":"Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy","volume":"66","author":"Sander","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B162","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00262-009-0724-5","article-title":"Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors","volume":"59","author":"Szczepanski","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B163","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3389\/fimmu.2017.00931","article-title":"In vitro culture with interleukin-15 leads to expression of activating receptors and recovery of natural killer cell function in acute myeloid leukemia patients","volume":"8","author":"Sanchez-Correa","year":"2017","journal-title":"Front Immunol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2014-02-556837","article-title":"Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15","volume":"124","author":"Imamura","year":"2014","journal-title":"Blood."},{"key":"B165","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4049\/jimmunol.1800086","article-title":"Emergence of NK cell hyporesponsiveness after two IL-15 stimulation cycles","volume":"201","author":"Frutoso","year":"2018","journal-title":"J Immunol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1172\/JCI125916","article-title":"Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming","volume":"130","author":"Merino","year":"2019","journal-title":"J Clin Invest"},{"key":"B167","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3109\/10428199509059647","article-title":"Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha","volume":"18","author":"Pawelec","year":"1995","journal-title":"Lymphoma"},{"key":"B168","doi-asserted-by":"publisher","first-page":"31959","DOI":"10.18632\/oncotarget.16657","article-title":"Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition","volume":"8","author":"Raneros","year":"2017","journal-title":"Oncotarget"},{"key":"B169","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2015-11-680546","article-title":"Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts","volume":"127","author":"Vasu","year":"2016","journal-title":"Blood."},{"key":"B170","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood-2017-06-790204","article-title":"Decitabine enhances targeting of AML cells by CD34(+) progenitor-derived NK cells in NOD\/SCID\/IL2Rg(null) mice","volume":"131","author":"Cany","year":"2018","journal-title":"Blood."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2007-07-101311","article-title":"NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities","volume":"111","author":"Diermayr","year":"2008","journal-title":"Blood."},{"key":"B172","doi-asserted-by":"publisher","first-page":"11154","DOI":"10.1038\/ncomms11154","article-title":"Repression of GSK3 restores NK cell cytotoxicity in AML patients","volume":"7","author":"Parameswaran","year":"2016","journal-title":"Nat Commun"},{"key":"B173","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CMAR.S81310","article-title":"Expanding role of lenalidomide in hematologic malignancies","volume":"7","author":"Ghosh","year":"2015","journal-title":"Cancer Manag Res"},{"key":"B174","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1200\/JCO.2010.30.8387","article-title":"Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed\/refractory solid tumors or myelodysplastic syndrome: AA children's oncology group phase I consortium report","volume":"29","author":"Berg","year":"2011","journal-title":"J Clin Oncol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3389\/fimmu.2018.00977","article-title":"Immunomodulatory drugs exert anti-leukemia effects in acute myeloid leukemia by direct and immunostimulatory activities","volume":"9","author":"Le Roy","year":"2018","journal-title":"Front Immunol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"B177","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00432-015-2101-4","article-title":"Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia","volume":"142","author":"El Missiry","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front Immunol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/hon.2034","article-title":"Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study","volume":"31","author":"Uchiyama","year":"2013","journal-title":"Hematol Oncol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.3389\/fimmu.2018.03152","article-title":"NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia","volume":"9","author":"Chang","year":"2018","journal-title":"Front Immunol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.3892\/ol.2017.7720","article-title":"Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib","volume":"15","author":"Jo","year":"2018","journal-title":"Oncol Lett"},{"key":"B183","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B184","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood."},{"key":"B185","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall'Ozzo","year":"2004","journal-title":"Cancer Res"},{"key":"B186","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"key":"B187","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"key":"B188","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3324\/haematol.2018.188193","article-title":"The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia\/myelodysplastic syndrome patients and healthy donors","volume":"103","author":"Mani","year":"2018","journal-title":"Haematologica"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1182\/blood-2012-12-475194","article-title":"Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells","volume":"123","author":"Nievergall","year":"2014","journal-title":"Blood."},{"key":"B191","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1038\/leu.2014.128","article-title":"Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC","volume":"28","author":"Busfield","year":"2014","journal-title":"Leukemia"},{"key":"B192","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3324\/haematol.2014.113092","article-title":"Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice","volume":"100","author":"Lee","year":"2015","journal-title":"Haematologica"},{"key":"B193","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/leu.2016.194","article-title":"An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia","volume":"31","author":"Koerner","year":"2017","journal-title":"Leukemia"},{"key":"B194","doi-asserted-by":"publisher","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","article-title":"Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS","volume":"120","author":"Barreyro","year":"2012","journal-title":"Blood."},{"key":"B196","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","article-title":"Selective killing of candidate AML stem cells by antibody targeting of IL1RAP","volume":"121","author":"Askmyr","year":"2013","journal-title":"Blood."},{"key":"B197","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.1073\/pnas.1422749112","article-title":"Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia","volume":"112","author":"\u00c5gerstam","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B198","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","article-title":"IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models","volume":"128","author":"\u00c5gerstam","year":"2016","journal-title":"Blood."},{"key":"B199","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","article-title":"Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition","volume":"19","author":"Wiernik","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B200","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B201","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1182\/blood-2014-05-570291","article-title":"Can Treg elimination enhance NK cell therapy for AML?","volume":"123","author":"Rooney","year":"2014","journal-title":"Blood."},{"key":"B202","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","article-title":"CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets","volume":"123","author":"Gleason","year":"2014","journal-title":"Blood."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1182\/bloodadvances.2017012369","article-title":"161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS","volume":"2","author":"Sarhan","year":"2018","journal-title":"Blood Adv"},{"key":"B204","doi-asserted-by":"publisher","first-page":"821","DOI":"10.4049\/jimmunol.1201792","article-title":"Receptor activator for NF-kappaB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance","volume":"190","author":"Schmiedel","year":"2013","journal-title":"J Immunol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest"},{"key":"B206","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2009-02-206532","article-title":"Preclinical characterization of 1\u20137F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells","volume":"114","author":"Romagn\u00e9","year":"2009","journal-title":"Blood."},{"key":"B207","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1182\/blood-2012-06-437558","article-title":"A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission","volume":"120","author":"Vey","year":"2012","journal-title":"Blood."},{"key":"B208","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-12-0668","article-title":"Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands","volume":"18","author":"Chan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B209","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-16-1108","article-title":"Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma","volume":"22","author":"Carlsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B210","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3324\/haematol.2015.135301","article-title":"Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells","volume":"101","author":"Ruggeri","year":"2016","journal-title":"Haematologica"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02357\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T13:46:04Z","timestamp":1695303964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02357\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":210,"alternative-id":["10.3389\/fimmu.2019.02357"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02357","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"article-number":"2357"}}